



PRESS RELEASE

Alpha IVF Group's IPO subscribed by 2.73 times

- *Fertility care specialist group received total applications worth RM169.6 million for public tranche*
- *To list on the ACE Market of Bursa Malaysia Securities Berhad on 22 March 2024*
- *Intends to adopt dividend policy of distributing at least 60.0% of annual audited profit after tax attributable to shareholders*

KUALA LUMPUR, Malaysia, 12 March 2024 - Fertility care specialist, Alpha IVF Group Berhad ("Alpha IVF Group") and its subsidiaries (collectively referred to as "the Group" or "阿儿法国际辅助生殖集团") has garnered enthusiasm for its Initial Public Offering (IPO) on the ACE Market of Bursa Malaysia Securities Berhad (Bursa Malaysia), with the public tranche subscribed by 2.73 times.

Alpha IVF Group received a total of 6,894 applications for 530.1 million shares, with a total value of RM169.6 million, versus the 194.4 million shares that were made available for application by the Malaysian public.

"The over subscription of our IPO by the Malaysian public signifies the confidence of the investing community in our expansion plans and prospects for growth. With their belief in our vision and mission, we stand ready to embark on this next chapter of growth, furthering our commitment to advancing In-Vitro Fertilisation (IVF) and fulfilling dreams of parenthood.

We are still primarily focused on growing our Group locally and internationally. We have high hopes for our capacity to fulfill the increasing demand for IVF services, particularly as more overseas patients visit our centres for treatment."

Dato' Dr Colin Lee Soon Soo (拿督李顺树医生)
Group Managing Director, Alpha IVF

According to Vital Factor Consulting's independent market research, the resurgence of the medical tourism industry following the border reopening has led to an average annual growth rate of 8.2% between 2020 and 2022 in the private health sector. The first nine months of 2023 saw the private health sector growing by 9.0% compared to the same period in 2022, suggesting an unabated need for healthcare services, which include the fertility treatment services provided by Alpha IVF Group.

The Malaysia Healthcare Tourism Council has identified fertility treatment as an area for medical tourism promotion. The recognition is expected to fuel expansion within the IVF industry.

Alpha IVF Group's IPO consists of a public issue of 364.5 million new ordinary shares along with an offer-for-sale of 1.1 billion existing shares, at an issue price of 0.32 sen per ordinary share.

The overall value of the IPO deal is worth RM466.6 million, with Alpha IVF Group receiving RM116.6 million and the offerors receiving the remaining RM349.9 million. Out of the total proceeds of RM116.6 million, RM72.8 million will be utilised to develop new IVF centres, satellite clinics, and sales representative offices as part of their domestic and global expansion strategy.



A further RM15.7 million will be allocated for expansion and upgrade of existing specialist centres, facilities, and corporate office; RM2.2 million for research and development (R&D), as well as the remaining RM25.9 million for general working capital, general corporate purposes, and defraying of listing expenses.

In line with the Group's objective to enhance shareholder value, Alpha IVF Group is committed to generously rewarding its shareholders. The Group intends to adopt a dividend policy, aiming to distribute at least 60% of the annual net profit for shareholders to participate in the Group's growth.

Alpha IVF Group is slated for listing on the ACE Market of Bursa Malaysia on 22 March 2024.

AmlInvestment Bank Berhad serves as the principal adviser, sponsor, lead bookrunner, and sole underwriter for the Group's IPO exercise.

About Alpha IVF Group Berhad ("Alpha IVF Group")

Alpha IVF Group is one of the largest fertility care specialists, currently operating in Malaysia and Singapore. The group primarily focuses on Assisted Reproductive Services (ARS), with a strong emphasis on In-vitro Fertilisation (IVF). Presently, the group operates two specialist centres in Malaysia - Alpha International Women's Specialists Sdn Bhd ("Alpha KL") in Kuala Lumpur and Genesis Specialists Sdn Bhd ("Genesis") in Penang - and one in Singapore known as Alpha International Women's Specialists (Singapore) Pte Ltd ("Alpha Singapore").

In addition to IVF, Alpha IVF Group provides various assisted reproductive procedures, including intracytoplasmic sperm injection, intrauterine insemination, diagnostics, testing, screening procedures, and cryopreservation of eggs, sperms, and embryos.

Since its inception in 2011, Alpha IVF Group has earned a strong reputation, with its brand synonymous with exceptional success rates in IVF. The high pregnancy rates are attributed to the group's robust foundation, known as the "system of systems," and its five strategic pillars: leading medical specialists, highly skilled embryologists, continuous research and development, innovative techniques, and cutting-edge laboratory equipment.

Alpha IVF Group's operations have provided IVF services to international patients from Indonesia, China, Singapore, the Middle East, Australia, and other countries. The group has also pioneered numerous innovations leading to improved pregnancy rates and is actively involved in utilizing Artificial Intelligence technology to enhance embryo selection for higher IVF success rates.

**Issued for and on behalf of ALPHA IVF GROUP BERHAD by Aquilas Advisory (Malaysia) Sdn Bhd.
For media enquiries, please contact:**

Ms. Azja Delana

azja@aquilas.com.my

T: 03-2711 1391/ 019-5886 088